Literature DB >> 22212942

Role of radiofrequency ablation in the treatment of hepatocellular carcinoma: experience of a cancer center in China.

Min-Shan Chen1, Zhen-Wei Peng, Li Xu, Yao-Jun Zhang, Hui-Hong Liang, Jin-Qing Li.   

Abstract

Radiofrequency ablation (RFA) has become an important treatment for hepatocellular carcinoma (HCC). The good candidates for RFA are patients with HCC at an early stage (solitary tumor ≤ 5 cm in diameter or ≤ 3 nodules ≤ 3 cm in diameter). Several clinical trials have shown that RFA is effective in resection for the treatment of small HCC. Until now, RFA has been widely used as a radical treatment for small HCC. RFA also plays an important role in the multidisciplinary treatment of HCC and is usually combined with other therapies such as resection, vascular intervention, intratumor ethanol injection, radiotherapy, chemotherapy, targeted drug therapy, and biological immune therapy. In this study, we will introduce our experience of RFA in the treatment of HCC in a cancer center in China.
Copyright © 2011 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2011        PMID: 22212942     DOI: 10.1159/000333268

Source DB:  PubMed          Journal:  Oncology        ISSN: 0030-2414            Impact factor:   2.935


  4 in total

1.  Radiofrequency ablation of hepatocellular carcinoma sized > 3 and ≤ 5 cm: is ablative margin of more than 1 cm justified?

Authors:  Shan Ke; Xue-Mei Ding; Xiao-Jun Qian; Yi-Ming Zhou; Bao-Xin Cao; Kun Gao; Wen-Bing Sun
Journal:  World J Gastroenterol       Date:  2013-11-14       Impact factor: 5.742

2.  Radiofrequency ablation for single hepatocellular carcinoma 3 cm or less as first-line treatment.

Authors:  Jun Gao; Shao-Hong Wang; Xue-Mei Ding; Wen-Bing Sun; Xiao-Long Li; Zong-Hai Xin; Chun-Min Ning; Shi-Gang Guo
Journal:  World J Gastroenterol       Date:  2015-05-07       Impact factor: 5.742

3.  Long-term survival analysis in combined transarterial embolization and stereotactic body radiation therapy versus stereotactic body radiation monotherapy for unresectable hepatocellular carcinoma >5 cm.

Authors:  Ting-Shi Su; Huan-Zhen Lu; Tao Cheng; Ying Zhou; Yong Huang; Ying-Chuan Gao; Min-Yang Tang; Hua-Yan Jiang; Zu-Ping Lian; En-Cun Hou; Ping Liang
Journal:  BMC Cancer       Date:  2016-11-03       Impact factor: 4.430

4.  Prospective, single-center cohort study analyzing the efficacy of complete laparoscopic resection on recurrent hepatocellular carcinoma.

Authors:  Jie Zhang; Zhong-Guo Zhou; Zhong-Xi Huang; Ke-Li Yang; Jian-Cong Chen; Jin-Bin Chen; Li Xu; Min-Shan Chen; Yao-Jun Zhang
Journal:  Chin J Cancer       Date:  2016-03-08
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.